Research and Development
Merck to Build EUR 300-Million Research Center
The pharmaceuticals and chemicals giant is investing a hefty nine-figure in a state-of-the-art facility in its home city of Darmstadt.
May 06, 2024
Merck’s “Advanced Research Center” is part of an EUR 1.5 billion investment project in Darmstadt.
The newly built facility is expected to be operational in 2027. One focus of the research envisioned at the center will be mRNA technology.
The project is one of many major pharmaceuticals projects announced in southern and southwestern Germany recently. Eli Lilly, NovoNordisk, BioNTech, AbbVie, Daiichi Sankyo and Roche are all currently in the process of increasing their involvement in Germany.
At Merck’s ground-breaking ceremony, German Chancellor Olaf Scholz called it a “commitment to Germany as a strong pharma, industrial and research location.”
